Innovative technologies and services for pharma & biotech
HWI group offers a broad technological and analytical portfolio for the development, manufacturing and analytical testing of medicinal products with small and large molecules.
Laboratory services with a focus on product development
Our strength is the development and validation of analytical methods, batch release and stability studies, testing concepts for impurities and in solving complex analytical issues.
Formulation development for small and large molecules
The HWI technology platform offers innovative solutions for fast and cost-efficient development of parenteral, intranasal and oral formulations for small and large active ingredients.
We take over operative activities and advise on pharmacovigilance in the life cycle and clinical trials of medicinal products and medical devices. We digitalise your PV processes and optimise your established systems.
Manufacturing, Packaging, approval testing, QP batch release and distribution of clinical investigational medicinal products for solid, semi-solid and liquid dosage forms.
Manufacturing of non-sterile solutions, micro- and nanosuspensions up to 100 kg batch size
Manufacturing of oral solid dosage forms up to 75 kg batch size
Customised primary and secondary packaging
Labelling of primary and secondary packaging
Randomisation
QP batch release
GMP release- and stability testing (according to ICH)
We provide regulatory support for the development of medicinal products and combination products up to marketing authorisation and beyond with the following services:
Regulatory strategy of product development
Support in the preparation of IMPD, IB, marketing authorisation dossiers
After marketing authorisation, we provide regulatory support with:
For the conduct of non-clinical in vivo and in vitro studies, we produce your formulation on a small scale under GMP conditions. With our partner institute, the Institute of Biochemistry and Molecular Biology at the University of Bonn, headed by Prof. Dr. Häberlein, we provide advice and support in the preclinical strategy and the conduct of preclinical studies on efficacy and tolerability as well as the elucidation of mechanisms of action (mode of action) in cell cultures or in animals.
We provide regulatory support for the development of medicinal products and combination products up to marketing authorisation and beyond with the following services.
Regulatory strategy of product development
Support in preparing IMPD, IB, marketing authorisation dossiers
The quality of an active pharmaceutical ingredient is characterised by a number of chemical and physical characteristics that have a decisive influence on the quality of the finished product, its bioavailability, its stability and its other effects. With the aim of achieving optimal drug quality, it is essential to know the chemical and physical characteristics of the active ingredient in the early phase of drug development and to optimise them if necessary.
With the experience of many years and our large pool of analytical technologies and methods, we characterise your active substance and define these active substance properties required for optimal drug quality.
CMC development
We support you in the development and optimisation of solid, semi-solid and liquid dosage forms. Our spectrum ranges from tablets, hard capsules, film-coated tablets and granules to solutions and gels to technologically highly sophisticated formulations with poorly soluble active ingredients such as micro- and nanosuspensions. In addition to galenic development, our strengths are in analytical method development and regulatory support. In particular, we emphasise the wide range of chemical and physical analytical techniques that make the development process faster and more efficient. Process development and optimisation are among our core competencies. We always have in mind the scalability to later large-scale production. In addition to our expertise in CMC development, you benefit from our extensive knowledge and experience in quality, preclinical and regulatory as well as our network for clinical development
Non-clinic
For the conduct of non-clinical in vivo and in vitro studies, we produce your formulation on a small scale under GMP conditions. With our partner institute, the Institute of Biochemistry and Molecular Biology at the University of Bonn, headed by Prof. Dr. Häberlein, we provide advice and support in the preclinical strategy and the conduct of preclinical studies on efficacy and tolerability as well as the elucidation of mechanisms of action (mode of action) in cell cultures or in animals.
Phase 1
We support you in preparation and implementation of your clinical trials and provide you with your clinical trial medication in accordance with applicable pharmaceutical standards and the highest quality standards. From clinical conception to manufacturing, analytical release testing and QP batch release to distribution to the study centre, HWI is your reliable partner.
If you have a need to develop or optimise your product before the start of the clinical trial, please have a look at our CMC develoment to find out how HWI can support you.
Phase 2
We support you in preparation and implementation of your clinical trials and provide you with your clinical trial medication in accordance with applicable pharmaceutical standards and the highest quality standards. From clinical conception to manufacturing, analytical release testing and QP batch release to distribution to the study centre, HWI is your reliable partner.
If you have a need to develop or optimise your product before the start of the clinical trial, please have a look at our CMC develoment to find out how HWI can support you.
Phase 3
We support you in preparation and implementation of your clinical trials and provide you with your clinical trial medication in accordance with applicable pharmaceutical standards and the highest quality standards. From clinical conception to manufacturing, analytical release testing and QP batch release to distribution to the study centre, HWI is your reliable partner.
If you have a need to develop or optimise your product before the start of the clinical trial, please have a look at our CMC develoment to find out how HWI can support you.
Marketing authorisation
We support the marketing authorisation process with our broad expertise and many years of experience in drug development and manufacturing.
Product life-cycle management
Market changes and constantly changing regulatory requirements place manufacturers under permanent pressure to adapt or optimise medicinal products that are already being marketed.
The change management required for any changes to the product is also subject to strict regulatory requirements.
For your successful change management we offer:
Process and product optimisation
Upscaling
Production validation
GAP analysis
Product transfer (site transfer or tech transfer)
Method transfer
Regulatory compliance review
Efficient implementation of new regulatory requirements
The HWI group is an innovative service provider for Pharma & Biotech
The HWI group offers a broad range of individual and specialised pharmaceutical services for the pharma and biotech sector, particularly for active ingredients and medicinal products. Benefit from our long-standing experience in laboratory services, pharmacovigilance, QP services and drug development.
Durch die Ansicht des Videos findet eine Datenübertragung an YouTube in die USA statt. Dort wird kein den europäischen Standards entsprechendes
Datenschutzniveau gewährleistet. Bitte klicken Sie hier, wenn Sie das Video ansehen möchten. Sie können Ihre Einwilligung jederzeit über einen Link
in unserer Datenschutzerklärung mit Wirkung für die Zukunft widerrufen.
Tableting under containment
X
Datenschutzhinweis
Durch die Ansicht des Videos findet eine Datenübertragung an YouTube in die USA statt. Dort wird kein den europäischen Standards entsprechendes
Datenschutzniveau gewährleistet. Bitte klicken Sie hier, wenn Sie das Video ansehen möchten. Sie können Ihre Einwilligung jederzeit über einen Link
in unserer Datenschutzerklärung mit Wirkung für die Zukunft widerrufen.
Manufacturing and lyophilisation of a nanosuspension
X
Datenschutzhinweis
Durch die Ansicht des Videos findet eine Datenübertragung an YouTube in die USA statt. Dort wird kein den europäischen Standards entsprechendes
Datenschutzniveau gewährleistet. Bitte klicken Sie hier, wenn Sie das Video ansehen möchten. Sie können Ihre Einwilligung jederzeit über einen Link
in unserer Datenschutzerklärung mit Wirkung für die Zukunft widerrufen.
In order to continuously improve and make our website more attractive, we would like to analyze your usage behavior on the website. For this purpose we use Matomo Analytics, which sets a session cookie for the duration of the website visit, which is automatically deleted when you leave the website. Please let us know whether you agree to this. You can withdraw your consent at any time via a link in our privacy policy with effect for the future.Privacy policy.